Tertiary lymphoid structures in cancers: Prognostic value, regulation, and manipulation for therapeutic intervention

Frontiers in Immunology

Volumn 7, Issue OCT, 2016, Pages

  Sautès Fridman, Catherine ^a,b,c   Lawand, Myriam ^a,b,c   Giraldo, Nicolas A ^a,b,c   Kaplon, Hélène ^a,b,c   Germain, Claire ^a,b,c   Fridman, Wolf Herman ^a,b,c   Dieu Nosjean, Marie Caroline ^a,b,c  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Adaptive immune response; Cancer; Chemokine; Tertiary lymphoid structure; Tumor microenvironment

Indexed keywords

ALICAFORSEN; BAMINERCEPT; CXCL13 CHEMOKINE; CXCL16 CHEMOKINE; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; PATECLIZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SECONDARY LYMPHOID TISSUE CHEMOKINE; VASCULOTROPIN;

BREAST TUMOR; CANCER GRADING; CANCER PROGNOSIS; CELL AGGREGATION; CLINICAL TRIAL (TOPIC); GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPHATIC SYSTEM; NONHUMAN; ORGANOGENESIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SYNOVITIS; TERTIARY LYMPHOID STRUCTURE;

EID: 84997108103     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00407     Document Type: Short Survey

References (70)

1. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 26(27):4410-7. doi:10.1200/JCO.2007.15.0284.
2. Germain C, Gnjatic S, Tamzalit F, Knockaert S, Remark R, Goc J, et al. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med (2014) 189(7):832-44. doi:10.1164/rccm.201309-1611OC.
3. Coppola D, Nebozhyn M, Khalil F, Dai H, Yeatman T, Loboda A, et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am J Pathol (2011) 179(1):37-45. doi:10.1016/j.ajpath.2011.03.007.
4. Cipponi A, Mercier M, Seremet T, Baurain JF, Théate I, van den Oord J, et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res (2012) 72(16):3997-4007. doi:10.1158/0008-5472.CAN-12-1377.
5. de Chaisemartin L, Goc J, Damotte D, Validire P, Magdeleinat P, Alifano M, et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res (2011) 71(20):6391-9. doi:10.1158/0008-5472.CAN-11-0952.
6. Martinet L, Garrido I, Girard JP. Tumor high endothelial venules (HEVs) predict lymphocyte infiltration and favorable prognosis in breast cancer. Oncoimmunology (2012) 1(5):789-90. doi:10.4161/onci.19787.
7. Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, et al. High endothelial venules (HEVs) in human melanoma lesions: major gateways for tumor-infiltrating lymphocytes. Oncoimmunology (2012) 1(6):829-39. doi:10.4161/onci.20492.
8. Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, et al. Human solid tumors contain high endothelial venules: association with T-and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res (2011) 71(17):5678-87. doi:10.1158/0008-5472.CAN-11-0431.
9. Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8 + T cells. Cancer Res (2014) 74(3):705-15. doi:10.1158/0008-5472.CAN-13-1342.
10. Hosmalin A, Sautès-Fridman C, Fougereau M, Yssel H, Fischer A. 50(th) Anniversary of the French Society for Immunology (SFI). Eur J Immunol (2016) 46(7):1545-7. doi:10.1002/eji.201670073.
11. Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I, Girard JP. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer. J Immunol (2013) 191(4):2001-8. doi:10.4049/jimmunol.1300872.
12. Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 123(7):2873-92. doi:10.1172/JCI67428.
13. Lee HJ, Park IA, Song IH, Shin SJ, Kim JY, Yu JH, et al. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J Clin Pathol (2016) 69(5):422-30. doi:10.1136/jclinpath-2015-203089.
14. Väyrynen JP, Sajanti SA, Klintrup K, Mäkelä J, Herzig KH, Karttunen TJ, et al. Characteristics and significance of colorectal cancer associated lymphoid reaction. Int J Cancer (2014) 134(9):2126-35. doi:10.1002/ijc.28533.
15. Remark R, Alifano M, Cremer I, Lupo A, Dieu-Nosjean MC, Riquet M, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res (2013) 19(15):4079-91. doi:10.1158/1078-0432.CCR-12-3847.
16. McMullen TPW, Lai R, Dabbagh L, Wallace TM, de Gara CJ. Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules. Clin Exp Immunol (2010) 161(1):81-8. doi:10.1111/j.1365-2249.2010.04147.x.
17. Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res (2014) 20(8):2147-58. doi:10.1158/1078-0432.CCR-13-2590.
18. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 39(4):782-95. doi:10.1016/j.immuni.2013.10.003.
19. Hennequin A, Derangère V, Boidot R, Apetoh L, Vincent J, Orry D, et al. Tumor infiltration by Tbet + effector T cells and CD20 + B cells is associated with survival in gastric cancer patients. Oncoimmunology (2016) 5(2):e1054598. doi:10.1080/2162402X.2015.1054598.
20. Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother (2007) 56(9):1459-69. doi:10.1007/s00262-007-0286-3.
21. Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, et al. 12-chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep (2012) 2:765. doi:10.1038/srep00765.
22. Wirsing AM, Rikardsen OG, Steigen SE, Uhlin-Hansen L, Hadler-Olsen E. Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma. BMC Clin Pathol (2014) 14:38. doi:10.1186/1472-6890-14-38.
23. Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br J Cancer (2015) 112(11):1782-90. doi:10.1038/bjc.2015.145.
24. Giraldo NA, Becht E, Pagès F, Skliris G, Verkarre V, Vano Y, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res (2015) 21(13):3031-40. doi:10.1158/1078-0432.CCR-14-2926.
25. Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol (2015) 16(12):1235-44. doi:10.1038/ni.3290.
26. Goeppert B, Frauenschuh L, Zucknick M, Stenzinger A, Andrulis M, Klauschen F, et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer (2013) 109(10):2665-74. doi:10.1038/bjc.2013.610.
27. Meshcheryakova A, Tamandl D, Bajna E, Stift J, Mittlboeck M, Svoboda M, et al. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One (2014) 9(6):e99008. doi:10.1371/journal.pone.0099008.
28. Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautès-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev (2016) 271(1):260-75. doi:10.1111/imr.12405.
29. Dieu-Nosjean MC, Goc J, Giraldo NA, Sautès-Fridman C, Fridman WH. Tertiary lymphoid structures in cancer and beyond. Trends Immunol (2014) 35(11):571-80. doi:10.1016/j.it.2014.09.006.
30. Sautès-Fridman C, Fridman WH. TLS in tumors: what lies within. Trends Immunol (2016) 37(1):1-2. doi:10.1016/j.it.2015.12.001.
31. Gräbner R, Lötzer K, Döpping S, Hildner M, Radke D, Beer M, et al. Lymphotoxin beta receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE-/-Mice. J Exp Med (2009) 206(1):233-48. doi:10.1084/jem.20080752.
32. Thaunat O, Field AC, Dai J, Louedec L, Patey N, Bloch MF, et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci U S A (2005) 102(41):14723-8. doi:10.1073/pnas.0507223102.
33. Matsuda Y, Wang X, Oishi H, Guan Z, Saito M, Liu M, et al. Spleen tyrosine kinase modulates fibrous airway obliteration and associated lymphoid neogenesis after transplantation. Am J Transplant (2016) 16(1):342-52. doi:10.1111/ajt.13442.
34. Browning JL, Allaire N, Ngam-Ek A, Notidis E, Hunt J, Perrin S, et al. Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity (2005) 23(5):539-50. doi:10.1016/j.immuni.2005.10.002.
35. Liao S, Ruddle NH. Synchrony of high endothelial venules and lymphatic vessels revealed by immunization. J Immunol (2006) 177(5):3369-79. doi:10.4049/jimmunol.177.5.3369.
36. Kumar V, Scandella E, Danuser R, Onder L, Nitschké M, Fukui Y, et al. Global lymphoid tissue remodeling during a viral infection is orchestrated by a B cell-lymphotoxin-dependent pathway. Blood (2010) 115(23):4725-33. doi:10.1182/blood-2009-10-250118.
37. Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature (2011) 479(7374):542-6. doi:10.1038/nature10540.
38. Wendland M, Willenzon S, Kocks J, Davalos-Misslitz AC, Hammerschmidt SI, Schumann K, et al. Lymph node T cell homeostasis relies on steady state homing of dendritic cells. Immunity (2011) 35(6):945-57. doi:10.1016/j.immuni.2011.10.017.
39. Sozzani S, Rusnati M, Riboldi E, Mitola S, Presta M. Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol (2007) 28(9):385-92. doi:10.1016/j.it.2007.07.006.
40. Webster B, Ekland EH, Agle LM, Chyou S, Ruggieri R, Lu TT. Regulation of lymph node vascular growth by dendritic cells. J Exp Med (2006) 203(8):1903-13. doi:10.1084/jem.20052272.
41. Benahmed F, Chyou S, Dasoveanu D, Chen J, Kumar V, Iwakura Y, et al. Multiple CD11c + cells collaboratively express IL-1β to modulate stromal vascular endothelial growth factor and lymph node vascular-stromal growth. J Immunol (2014) 192(9):4153-63. doi:10.4049/jimmunol.1301765.
42. Marinkovic T, Garin A, Yokota Y, Fu YX, Ruddle NH, Furtado GC, et al. Interaction of mature CD3 + CD4 + T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. J Clin Invest (2006) 116(10):2622-32. doi:10.1172/JCI28993.
43. Peske JD, Thompson ED, Gemta L, Baylis RA, Fu YX, Engelhard VH. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat Commun (2015) 6:7114. doi:10.1038/ncomms8114.
44. Grogan JL, Ouyang W. A role for Th17 cells in the regulation of tertiary lymphoid follicles. Eur J Immunol (2012) 42(9):2255-62. doi:10.1002/eji.201242656.
45. Rangel-Moreno J, Carragher DM, de la Luz Garcia-Hernandez M, Hwang JY, Kusser K, Hartson L, et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat Immunol (2011) 12(7):639-46. doi:10.1038/ni.2053.
46. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity (2011) 35(6):986-96. doi:10.1016/j.immuni.2011.10.015.
47. Roos AB, Sandén C, Mori M, Bjermer L, Stampfli MR, Erjefält JS. IL-17A is elevated in end-stage chronic obstructive pulmonary disease and contributes to cigarette smoke-induced lymphoid neogenesis. Am J Respir Crit Care Med (2015) 191(11):1232-41. doi:10.1164/rccm.201410-1861OC.
48. Deteix C, Attuil-Audenis V, Duthey A, Patey N, McGregor B, Dubois V, et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol (2010) 184(9):5344-51. doi:10.4049/jimmunol.0902999.
49. Cañete JD, Celis R, Yeremenko N, Sanmartí R, van Duivenvoorde L, Ramírez J, et al. Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. Arthritis Res Ther (2015) 17:173. doi:10.1186/s13075-015-0688-0.
50. Barone F, Nayar S, Campos J, Cloake T, Withers DR, Toellner KM, et al. IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc Natl Acad Sci U S A (2015) 112(35):11024-9. doi:10.1073/pnas.1503315112.
51. Jones GW, Bombardieri M, Greenhill CJ, McLeod L, Nerviani A, Rocher-Ros V, et al. Interleukin-27 inhibits ectopic lymphoid-like structure development in early inflammatory arthritis. J Exp Med (2015) 212(11):1793-802. doi:10.1084/jem.20132307.
52. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 12(4):298-306. doi:10.1038/nrc3245.
53. Becht E, Giraldo NA, Germain C, de Reyniès A, Laurent-Puig P, Zucman-Rossi J, et al. Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol (2016) 130:95-190. doi:10.1016/bs.ai.2015.12.002.
54. Kocks JR, Davalos-Misslitz AC, Hintzen G, Ohl L, Förster R. Regulatory T cells interfere with the development of bronchus-associated lymphoid tissue. J Exp Med (2007) 204(4):723-34. doi:10.1084/jem.20061424.
55. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, ArfiV, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 69(5):2000-9. doi:10.1158/0008-5472.CAN-08-2360.
56. Hindley JP, Jones E, Smart K, Bridgeman H, Lauder SN, Ondondo B, et al. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res (2012) 72(21):5473-82. doi:10.1158/0008-5472.CAN-12-1912.
57. Foo SY, Zhang V, Lalwani A, Lynch JP, Zhuang A, Lam CE, et al. Regulatory T cells prevent inducible BALT formation by dampening neutrophilic inflammation. J Immunol (2015) 194(9):4567-76. doi:10.4049/jimmunol.1400909.
58. Joshi NS, Akama-Garren EH, Lu Y, Lee DY, Chang GP, Li A, et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity (2015) 43(3):579-90. doi:10.1016/j.immuni.2015.08.006.
59. Mebius, Reina E. Organogenesis of lymphoid tissues. Nat Rev Immunol (2003) 3(4):292-303. doi:10.1038/nri1054.
60. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity (2002) 17(4):525-35. doi:10.1016/S1074-7613(02)00423-5.
61. Meier D, Bornmann C, Chappaz S, Schmutz S, Otten LA, Ceredig R, et al. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity (2007) 26(5):643-54. doi:10.1016/j.immuni.2007.04.009.
62. Seo YB, Im SJ, Namkoong H, Kim SW, Choi YW, Kang MC, et al. Crucial roles of interleukin-7 in the development of T follicular helper cells and in the induction of humoral immunity. J Virol (2014) 88(16):8998-9009. doi:10.1128/JVI.00534-14.
63. Lee LF, Logronio K, Tu GH, Zhai W, Ni I, Mei L, et al. Anti-IL-7 Receptor-a reverses established type 1 diabetes in non-obese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A (2012) 109(31):12674-9. doi:10.1073/pnas.1203795109.
64. Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol (2000) 165(4):1992-2000. doi:10.4049/jimmunol.165.4.1992.
65. Nomura T, Hasegawa H, Kohno M, Sasaki M, Fujita S. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes. Int J Cancer (2001) 91(5):597-606. doi:10.1002/1097-0215(200002)9999:9999<::AID-IJC1107>3.0.CO;2-J.
66. Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res (2006) 66(6):3205-13. doi:10.1158/0008-5472.CAN-05-3619.
67. Kuchen S, Robbins R, Sims GP, Sheng C, Phillips TM, Lipsky PE, et al. Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4 + T cell-B cell collaboration. J Immunol (2007) 179(9):5886-96. doi:10.4049/jimmunol.179.9.5886.
68. Attridge K, Wang CJ, Wardzinski L, Kenefeck R, Chamberlain JL, Manzotti C, et al. IL-21 inhibits T cell IL-2 production and impairs treg homeostasis. Blood (2012) 119(20):4656-64. doi:10.1182/blood-2011-10-388546.
69. Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med (2014) 6(221):221ra13. doi:10.1126/scitranslmed.3007323.
70. Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al. Immunotherapy converts non-immunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res (2014) 2(7):616-31. doi:10.1158/2326-6066.CIR-14-0027.